毛蕊花糖苷抗胶质母细胞瘤作用机制研究OA
Study on the Mechanism of Action of Acteoside Against Glioblastoma
目的 基于网络药理学与分子对接技术筛选毛蕊花糖苷(ACT)抗胶质母细胞瘤(GBM)的潜在靶点,并通过体外实验探究其抑制肿瘤恶性进展的作用及分子机制.方法 首先通过数据库筛选 ACT 的成分靶点以及 GBM 相关的疾病靶点,进而构建药物-靶点-疾病可视化网络和蛋白相互作用网络并进行 GO 和 KEGG 富集分析,采用分子对接对潜在的作用靶点进行验证.通过 CCK-8 实验检测细胞增殖活性,Transwell 实验检测细胞迁移与侵袭能力,Western blot 检测MAPK 通路关键蛋白 ERK、p-ERK 以及下游效应分子 MMP2、MMP9 的表达变化;进一步使用 MAPK 通路激动剂 EGF 进行挽救实验,验证通路在 ACT 作用中的功能地位.结果 网络药理学与分子对接提示 MMP2 和 MMP9 是 ACT 作用于GBM 的潜在关键靶点.体外实验显示,ACT 能抑制 GBM 细胞活力、迁移与侵袭能力,并下调 p-ERK、MMP2 和 MMP9 蛋白表达.并且 MAPK 通路激动剂 EGF 可逆转 ACT 对上述蛋白的表达及细胞表型的抑制作用.结论 ACT 可能通过抑制 MAPK 信号通路,下调 MMP2 与 MMP9 的表达,从而抑制 GBM 细胞的增殖、迁移与侵袭.本研究从计算预测到实验验证系统阐明了其作用机制,为将其开发为抗 GBM 药物提供理论依据.
Objective To screen the potential targets of Acteoside(ACT)against glioblastoma based on network pharmacology and molecular docking technology,and to explore its inhibitory effect on malignant progression and the underlying molecular mechanisms through in vitro experiments.Methods The component targets of ACT and disease-related targets of glioblastoma were first retrieved from databases to construct a drug-target-disease visualization network and a protein-protein interaction(PPI)network,followed by GO and KEGG enrichment analyses.Molecular docking was performed to validate potential interaction targets.Cell proliferation activity was assessed by CCK-8 assay,cell migration and invasion abilities were examined using Transwell assay,and Western blot was employed to detect the expression changes of key MAPK pathway proteins(ERK,p-ERK)and downstream effector molecules(MMP2,MMP9).Furthermore,a rescue experiment using the MAPK pathway agonist EGF was conducted to verify the functional role of the pathway in the action of ACT.Results Network pharmacol-ogy and molecular docking suggested that MMP2 and MMP9 are potential key targets of ACT in glioblastoma.In vitro experiments showed that ACT inhibited glioblastoma cell viability,migration,and invasion,and down-regulated the expression of p-ERK,MMP2,and MMP9 pro-teins.Moreover,the MAPK pathway agonist EGF reversed the inhibitory effects of ACT on the expression of these proteins and the associated cellular phenotypes.Conclusion ACT may inhibit the proliferation,migration,and invasion of glioblastoma cells by suppressing the MAPK signaling pathway and downregulating the expression of MMP2 and MMP9.This study systematically elucidates the mechanism of action from computational prediction to experimental validation,providing a theoretical basis for the development of ACT as an anti-glioblastoma drug.
尹鹏翔;蒋赛男;马婉璐;杨洁;陈洪国
湖北科技学院医学部药学院,湖北 咸宁 437100湖北科技学院医学部药学院,湖北 咸宁 437100湖北科技学院医学部药学院,湖北 咸宁 437100湖北科技学院核技术与化学生物学院湖北科技学院核技术与化学生物学院
医药卫生
毛蕊花糖苷胶质母细胞瘤侵袭网络药理学MAPK通路
ACTGlioblastomaInvasionNetwork pharmacologyMAPK pathway
《湖北科技学院学报(医学版)》 2026 (4)
295-300,6
湖北省自然科学基金项目(2024AFB1057,2021BBA098)
评论